Thursday, February 09, 2017 2:43:23 PM
A life saving therapy like Emricasan could have a price tag of $100K per annum per patient, like for cancer drugs. So in decompensated LC the potential global market is 5M x $100K = $500B. a 10% penetration in that market could mean $50B rev/annum or $10B in annual royalties to CNAT as per NVS deal, ie $100B market cap. Assuming 35M OS (only small dilution given that everything is paid by NVS), this would mean ca $3,000 PPS or 600 time current share price, and this could happen within 5 years from now., also because very little, if not null competition, is out there
http://www.medscape.com/viewarticle/737296
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM